<DOC>
	<DOCNO>NCT00253799</DOCNO>
	<brief_summary>The objective ass safety efficacy ( course 26 week ) 2 intra-articular ( IA ) Hylan GF-20 ( Synvisc ) injection addition customary care patient painful glenohumeral osteoarthritis .</brief_summary>
	<brief_title>A Safety Study Hylan GF-20 Treat Shoulder Osteoarthritis</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Pain</mesh_term>
	<mesh_term>Hylan</mesh_term>
	<criteria>• Be able provide write informed consent prior studyrelated procedure perform able understand comply requirement study . Agree receive fluoroscopically guide injection . Be men woman age 35 year old . If female childbearing age , must negative pregnancy test take oral contraceptive least one month prior treatment continue duration study ( include final study visit ) agree use 2 form contraception ; otherwise female must surgically sterile postmenopausal least one year . Have painful , noninflammatory unilateral osteoarthritis shoulder . OA contralateral shoulder permissible provide OA symptom great study joint . The presence soft tissue pathology ( e.g. , rotator cuff tear ) permit , evaluate MRI ( take within 6 month study entry ) . Report initial visual analogue pain score ( VAS ) ≥ 30 ≤ 80 . Have radiographic confirmation osteoarthritis shoulder prior baseline ( modified Kellgren Lawrence Numerical Grading System Grades II – IV ) radiograph perform within 12 week screen Have pain shoulder OA require frequent ( &gt; 3 days/week ) use analgesic NSAIDs least 8 week prior screen . • Pregnant , lactating , unwilling use adequate contraception . Prior viscosupplementation target shoulder joint within 1 year study entry . Known sensitivity avian protein component hyaluronan base infection device , steroid , lidocaine . Known Sensitivity contrast agent . Used systemic steroid intraarticular steroid injection target shoulder within last 3 month . Rapidly progressive disease . Acute disease trauma lead osteoarthritis joint within 2 year study entry . Presence primary inflammatory arthropathy ( e.g. , rheumatoid , psoriatic , gouty arthritis ) . Active skin soft tissue infection area injection site . Cervical spin disorder ( e.g. , radiculopathy ) symptomatic require active treatment within past 3 month . Any active musculoskeletal condition would impede measurement efficacy target shoulder joint ( fibromyalgia ) . Any major surgery , arthroplasty arthroscopy target shoulder within 26 week screen plan surgery within duration study . Septic arthritis joint within 3 month prior screen ; history septic arthritis target shoulder . Any significant chronic skin disorder could interfere evaluation injection site . Uncontrolled diabetes mellitus , diabetic neuropathy infectious complication . Active malignancy receive treatment . Taking warfarin parental anticoagulant therapy . Active asthma may require periodic treatment steroid study period . Use investigational drug , device , biologic within 12 week screen Patients ongoing litigation workman ’ compensation claim .</criteria>
	<gender>All</gender>
	<minimum_age>35 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2007</verification_date>
</DOC>